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Abstract 
Background: Low CD4+ recovery among HIV-positive individuals who achieve virologic 
suppression is common but has not been studied among individuals initiating treatment at CD4+ 
counts > 500 cells/mm3.  
Setting: United States, Africa, Asia, Europe & Israel, Australia, Latin America.  
Methods: Among immediate-ART participants in the Strategic Timing of AntiRetroviral Therapy 
trial, low CD4+ recovery was defined as a CD4+ increase < 50 cells/mm3 from baseline after 8 
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months despite viral load ≤ 200 copies/mL.  Risk factors for low recovery were investigated with 
logistic regression.  
Results: 39.7% of participants had low CD4+ recovery. Male gender (OR 1.53, p = 0.007), lower 
screening CD4+ (OR 1.09 per 100 fewer cells/mm3, p = 0.004), higher baseline CD8+ (OR 1.05 
per 100 more cells/mm3, p < 0.001), and lower HIV RNA (OR 1.93 per log10 decrease, p < 
0.001) were associated with low CD4+ recovery.  D-dimer had a quadratic association with low 
CD4+ recovery, with lowest odds occurring at 0.32 g/mL. At lower HIV RNA levels, odds of 
low recovery were elevated across levels of screening CD4+ count, but at higher levels, odds of 
low CD4+ recovery were greater among those with lower versus higher screening CD4+.       
Conclusion: Low CD4+ recovery is frequent among participants starting ART at high CD4+ 
counts.  Risk factors include male gender, lower screening CD4+ cell counts, higher CD8+ cell 
counts, and lower HIV RNA levels.  More follow-up is required to determine the impact of low 
CD4+ recovery on clinical outcomes.  
Key Words: Antiretroviral therapy, CD4, HIV, immune response 
 
 
Introduction 
In the majority of HIV-positive patients treated with antiretroviral therapy (ART), viral 
suppression is achieved and CD4+ counts recover to > 500 cells/mm3.1–7 The percentage of 
patients with a low CD4+ count recovery varies between 15% and 30% depending on the 
definition used and on the time period since the start of ART8–10. Among patients who initiate 
ART at low CD4+ counts,  low CD4+ recovery after initiation of ART is associated with 
increased risk for AIDS, serious non-AIDS diseases, and death8,11–15. Several risk factors for 
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failure to show a substantial increase in CD4+ counts have been well-characterized among 
patients who initiate ART at CD4+ levels < 500 cells/mm3. These risk factors include older age, 
lower HIV RNA level, hepatitis C co-infection, active hepatitis B co-infection , longer duration 
of HIV infection, and lower nadir CD4+ count8–11,16–19.  Genetic factors have also been cited as 
possible links to low CD4+ recovery14,19–23.    To our knowledge, the determinants of low CD4+ 
recovery following virologic suppression have not been studied specifically among patients who 
initiate ART at CD4+ counts > 500 cells/mm3.  
  The goal of this investigation is to estimate the prevalence of low CD4+ count recovery 
despite virologic suppression after 8 months of ART among participants with HIV who initiate 
ART at a CD4+ count > 500 cells/mm3, and to determine predictors of low recovery, including 
pre-ART CD4+ cell count.  This will be accomplished using participants randomized to the 
immediate ART treatment group in the Strategic Timing of Antiretroviral Treatment (START) 
trial13.  Since the number of clinical events in the immediate ART initiation group of the START 
was very low, we did not have the power to evaluate the clinical implication of low CD4 
recovery. 
 
Methods 
Design.  
The START trial was approved by the institutional review board or ethics committee at each 
participating site, and written informed consent was obtained from all study participants. The 
study design and baseline characteristics of participants in START have been reported 
previously13,24,25. In START, HIV-positive, ART-naïve participants with CD4+ counts > 500 
cells/mm3 were randomized to immediate initiation of ART (n = 2,325) or to deferred initiation 
until the CD4+ count declined to 350 cells/mm3 or AIDS developed (n = 2,359).  ART regimens 
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were selected by participants and their providers from a list of approved drug combinations 
derived from guidelines of the Department of Health and Human Services26. Participants were 
required to have two CD4+ counts > 500 cells/mm3 at least 2 weeks apart within 60 days before 
randomization. We refer to the first of these CD4+ counts as the screening CD4+ and the second 
as the baseline CD4+ count. In addition to CD4+ cell count, CD8+ cell count, and HIV RNA 
level were measured locally prior to randomization and at 1 month, 4 months, and every 4 
months of follow-up thereafter.  Similar to Baker et al.11 and Florence et al.16, low CD4+ 
recovery following ART initiation was defined as CD4+ increase < 50 cells/mm3 8 months after 
randomization despite HIV RNA ≤ 200 copies/mL at 8 months; high recovery was defined as 
CD4+ increase ≥ 50 cells/mm3 among those with an HIV RNA ≤ 200 copies/mL.  Those who do 
not achieve large gains in CD4+ count following the initiation of ART have also been referred to 
as immunologic non-responders. 
 
Statistical Analysis.  
If change is measured from baseline, the relationship of change in CD4+ count with baseline 
CD4+ count is influenced by measurement error and within-participant variability (i.e., 
regression to the mean)27,28.  To reduce the effect of regression to the mean for studying the 
association of CD4+ count change (value at 8 months minus baseline value) with pre-ART 
CD4+ count, we used two methods.  The first approach used the screening CD4+ count (the 1st 
of the two pre-ART counts), which was not used to calculate CD4+ count change, as the 
predictor of change in CD4+ count and of low CD4+ recovery.  Based on work by Ederer,29 we 
assumed  that if the correlation between baseline CD4+ count and 8 month CD4+ count was 
similar to the correlation between screening CD4+ count and 8 month CD4+ count, the effect of 
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regression to the mean could be largely eliminated with this approach. The bias in estimating an 
association between an initial value and a change from that initial value arises in part due to 
mathematical coupling: the initial value is both the predictor and is part of the derived response, 
and this can create bias in the estimated association. This can be partially avoided by using as a 
predictor a second “initial” value provided that it was obtained in close temporal proximity to the 
initial value from which change is measured. The second approach used  a method proposed by 
Blomqvist27,30 to estimate the association between “true” or “usual” pre-ART CD4+ cell count 
levels (with correction for measurement error and short-term intra-person variability) and change 
in CD4+ count.  The second approach has the advantage of not requiring two measurements of 
pre-ART CD4+ counts for assessing change.  However, it does require an estimate of the 
reliability coefficient (ratio of between person to total variability).  In this investigation, the 
reliability coefficient was estimated by the correlation of the screening and baseline CD4+ 
counts. 
Linear mixed effects models31 were used to analyze CD4+ differences between groups 
over follow-up. Risk factors for low CD4+ count recovery were studied with logistic regression; 
odds ratios (ORs) and 95% confidence intervals (CIs) are cited.  Because odds ratios are not 
good approximations of the relative risk when the outcome is common, relative risks from log-
binomial and Poisson regression models are also cited. Univariable (i.e., unadjusted) and 
multivariable (adjusted) analyses were carried out. As potential baseline (pre-ART) risk factors 
for low recovery, we considered age, gender, race (Asian, black, Hispanic, white/other), 
geographic location, treatment regimen, body mass index (BMI, kg/m2), co-infection with 
hepatitis C, co-infection with hepatitis B, screening CD4+ count,  baseline CD8+ count,  HIV 
RNA level (copies/mL),  baseline interleukin-6 (IL-6, pg/mL), baseline D-dimer (g/mL), and 
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duration of time since HIV diagnosis. Geographic region was categorized as United States, 
Africa, Asia, Europe & Israel, Australia, or Latin America. Treatment regimen was categorized 
as non-nucleoside reverse transcriptase inhibitor (NNRTI) + 2 nucleoside reverse transcriptase 
inhibitors (NRTIs), protease inhibitor (PI) + 2 NRTIs, integrase inhibitor + 2 NRTIs, or other. 
The great majority of participants were prescribed tenofovir and emtricitabine as the 2 NRTIs.  
Thus, further categorization of this class of drugs was not carried out. (See supplemental table 
2,http://links.lww.com/QAI/B275 in reference 13 for further details of the treatment regimens 
used in START.) The adjusted analysis included all these variables. For variables with 
associations that changed between the univariable and multivariable models, we explored 
interactions among variables as possible explanations of the changes.  For continuous predictors, 
we checked linearity against the logit function using empirical logit plots: for each continuous 
predictor, observations were grouped based on deciles of the predictor, and observed logits of 
probability of low CD4+ recovery were plotted against the mean values of the predictor within 
each decile. All analyses were done with SAS statistical software, versions 9.4 (SAS Institute, 
Cary, NC, USA). 
 
Results 
Study Cohort 
Of the 2,325 participants randomized to the immediate ART group of START, 2,063 
started ART within 30 days of randomization; of these, 1,983 had a CD4+ count and HIV RNA 
level at the month 8 visit, and of these, 1,884 (95%) had an HIV RNA ≤ 200 copies/ml at month 
8. These 1,884 patients comprise the cohort for this study.  
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Overall, for these 1,884 participants, the mean (standard deviation) screening, baseline 
and 8-month CD4+ cell counts were 709 (191), 694 (193) and 806 (261) cell/mm3, respectively. 
The median (25th, 75th percentile) number of days between screening and baseline CD4+ counts 
was 21 (16, 33) days. Correlations between screening and 8-month CD4+ count and between 
baseline CD4+ count and 8 month CD4+ count were 0.51, and 0.50 respectively.  
Prevalence of Low CD4+ Count Recovery and Change in CD4+ Count Over Follow-up for 
those with Low versus High Recovery 
Among the 1,884 participants in the immediate ART group who had an HIV RNA ≤ 200 
copies/ml 8 months after initiating ART, 748 (39.7%; 95% CI: 37.5% to 42.0%) had low CD4+ 
recovery. The average change in CD4+ count from baseline to 8 months was -93 cells/mm3 (95% 
CI: -102 to -84) in low responders vs. +247 cells/mm3 (95% CI: 236 to 258) in high responders.  
Following an initial increase in CD4+ cell count for low responders and a decrease in CD4+ 
count for high responders between month 8 and month 12, which we attribute to regression to the 
mean, over 12 – 60 months of follow-up (median follow-up = 3.0 years, 25th and 75th percentiles 
are 2.3 and 4.1 years), the mean CD4+ count was 228 cells/mm3 higher in high responders than 
low responders (95% CI: 207 to 249) controlling for baseline CD4+, and CD4+ counts increased 
more rapidly among high responders with an average increase of 3.3 cells/mm3/month (95% CI: 
2.9 to 3.6) vs 2.2 cells/mm3/month in low responders (95% CI: 1.8 to 2.7) (Figure 1). Thirty-six 
months after initiating ART, only 17% of low responders had CD4+ counts over 1000 cells/mm3, 
vs. 37% of high responders (p < 0.0001 for difference).  
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Association of Pre-ART Screening and Baseline CD4+ Count with Change in CD4+ Count at 8 
Months 
Table 1 gives estimates of slopes for the regression of change in CD4+ cell count from 
baseline to 8 months on screening and baseline CD4+ cell count levels.  The slope is positive and 
not significant for screening CD4+ cell count indicating for each 100 cell higher screening CD4+ 
count, the change in CD4+ count at 8 months was +2.1 cells/mm3 greater. In contrast, as a result 
of regression to the mean, for baseline CD4+ cell count, the slope is negatively biased at -32.5 
cells/mm3 (95% CI: -37.8, -27.2; p < 0.001).  The slope estimated with Blomqvist’s method, 
which adjusts the baseline CD4+ count for measurement error, is similar to the slope for the 
screening CD4+ cell count: +1.7 cells/mm3 (95% CI: -11.6, +16.9; p = 0.82) for a 100 cell higher 
baseline CD4+ count.   
Similar to the results shown in Table 1, the univariate association between the percent 
with a low CD4+ response at 8 months and screening CD4+ cell count shows no clear 
relationship (p = 0.85 for trend) (Figure 2). 
 
Univariable and Multivariable Predictors of Low CD4+ Count Recovery 
Supplementary Table 1,http://links.lww.com/QAI/B275 gives baseline characteristics for 
those with low and high recovery. Table 2 shows the results for univariable and multivariable 
logistic regression models for baseline predictors of low CD4+ recovery. In multivariable 
analyses, males had significantly greater odds of low CD4+ recovery than females (odds ratio 
[OR] 1.53, p = 0.007), but the association was not significant in univariable analysis (OR 0.93, p 
= 0.47). The striking difference in the effect of gender between univariable and multivariable 
models is explained by the confounding effect of HIV RNA – itself a strong predictor of CD4+ 
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recovery - between females and males: the median (25th, 75th percentile) of log10 viral load was 
3.81 (3.05, 4.36) for females and 4.26 (3.69, 4.70) for males.  
In univariable analyses, black participants had significantly higher odds of low CD4+ 
recovery than white/other participants (OR 1.51, p < 0.001), and Africans had higher odds of low 
recovery than participants in the United States (OR 1.70, p = 0.004). In the multivariable model, 
black race was no longer significant; the association remained significant when African 
participants were compared with participants in the United States (OR 1.62, p = 0.043). The 
univariable OR for black vs. white/other was attenuated in the multivariable model because the 
model included both race and geographic region. In a multivariable model excluding geographic 
region but including all other variables (results not shown), the OR for black vs. white/other was 
1.34 (95% CI: 1.00 – 1.78, p = 0.047).  
 In univariable analysis, participants treated with a PI + 2 NRTIs had lower odds of low 
CD4+ recovery compared to participants treated with NNRTI + 2 NRTIs (OR 0.67, p = 0.002), 
but the effect was not significant in the multivariable model. The reduced association in the 
multivariable analysis is largely due to the adjustment for geographic region.  Participants in the 
three geographic areas with the lowest odds of low recovery (United States, Europe & Israel, and 
Australia) were significantly more likely to be treated with a PI + 2 NRTIs (  = 222.5, p  < 
0.001 for test of homogeneity). Aside from race and treatment regimen, odds ratios for other 
covariates considered were not materially modified with the exclusion of geographic region from 
the multivariable model.   
Higher baseline CD8+ was associated with increased odds of low CD4+ recovery in both 
univariable analysis (OR 1.03 per 100 more cells/mm3, p < 0.001) and multivariable analysis 
(OR 1.05 per 100 more cells/mm3, p < 0.001).  Lower baseline HIV RNA level was associated 
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with increased odds of low recovery in both univariable analysis (OR 1.68, p < 0.001) and in 
multivariable analysis (OR 1.93, p < 0.001). Time since HIV diagnosis was weakly associated 
with odds of low CD4+ recovery in univariable analysis (OR 1.04 per 1-year longer, p = 0.011) 
but not in multivariable analysis (OR 1.03, p = 0.15). 
As previously described, screening CD4+ cell count was not associated with CD4+ 
change at 8 months.  Similarly, in univariable analysis screening CD4+ was not associated with 
odds of low recovery (p = 0.85). However, in the multivariable model, lower screening CD4+ 
was associated with increased odds of low recovery (OR 1.09 per 100 fewer cells/mm3, p = 
0.004).  This was explored further and a significant interaction between screening CD4+ cell 
count and baseline HIV RNA level was found (p = 0.005 for interaction term from logistic model 
when both screening CD4+ and baseline log10 HIV RNA were continuous predictors for low 
recovery). Figure 3 illustrates the interaction. Among those with lower baseline HIV RNA levels, 
the association between screening CD4+ count and low CD4+ recovery at 8 months was weaker 
(red bars).  Similarly, we checked for an interaction between baseline CD8+ cell count and 
baseline HIV RNA levels (Supplemental Figure 1,http://links.lww.com/QAI/B275), but the 
effect of the interaction was not significant (p = 0.62). 
In univariable and multivariable analysis, we included a quadratic term for D-dimer, 
because empirical logit plots suggested a possible quadratic association between D-dimer and 
odds of low CD4+ recovery. Both analyses indicated a quadratic effect of D-dimer.  From the 
univariable analysis, the estimated odds of low CD4+ recovery were lowest for D-dimer of 0.27 
g/mL (median D-dimer was 0.32	g/mL); the odds of low CD4+ recovery for the 25th 
percentile (0.22	g/mL) and 75th percentile (0.50	g/mL) of D-dimer versus 0.27 g/mL were 
6.7% and 0.7% higher, respectively. From the multivariable analysis, the estimated odds of low 
AC
CE
PT
E
Copyright  201 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.9 
 12 
CD4+ recovery were lowest for D-dimer of 0.32 g/mL; the odds of low CD4+ recovery for the 
25th percentile and 75th percentile of D-dimer versus 0.32 g/mL were 11.5%% and 0.2% higher, 
respectively, assuming fixed values of all other variables.  
The empirical logit plots also suggested a possible quadratic effect of screening CD4+ 
(this is also suggested by Figure 2); a quadratic effect was found in univariable analysis (data not 
shown), but the association was no longer present after considering the interaction between 
screening CD4+ and viral load.  
Estimated relative risks for comparison with odds ratios are given in Supplementary 
Table 2,http://links.lww.com/QAI/B275.   Relative risks are lower than the odds ratios, but risk 
factors for low recovery identified from these analyses are similar.  
 
Conclusion 
 To our knowledge, this is the first study investigating the prevalence and risk factors for 
CD4+ recovery specifically among individuals who initiate ART at CD4+ counts > 500 
cells/mm3. We showed that low CD4+ recovery after starting ART at CD4+ counts > 500 
cells/mm3 is frequent despite virologic suppression, and the lower CD4+ cell counts following 
ART initiation for those with low recovery compared to those with high recovery at 8 months 
persisted through 5 years of follow-up.  Similar to other studies, we found that male gender32,33, 
lower screening CD4+ cell count16,33,34 and lower baseline HIV RNA11,16,35 increased the odds of 
low CD4+ recovery.  We also found that race and/or geographic region may be an important 
predictor of poor CD4 recovery and could inform studies to identify potential genetic or 
environmental etiologies. The association with screening CD4+ cell count was not large – for a 
100 cell lower screening count the odds of low response was increased by 9%.  In addition, we 
found that the association with pre-ART screening CD4+ count depends on HIV RNA level.   
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Associations of low CD4+ response with screening CD4+ counts were weaker among those with 
low HIV RNA levels.  This interaction and lack of recognition of the impact of measurement 
error and within-person variability on studies of the association between change and initial value 
(see below) may explain differences among studies of low responders, some which identified 
low baseline or nadir CD4+ count with low CD4+ recovery and some which did not. 
 While perhaps counter-intuitive, the finding that lower baseline HIV RNA increased the 
odds of low CD4+ recovery has been reported previously33. This effect may be due to prior 
innate suppression of HIV replication, such that lack of CD4 decline may have already been 
achieved, blunting any additional increase. This is in line with the findings that HLA-Bw4 is 
associated with lower HIV RNA during natural history and blunted CD4 response on cART19. 
One other possible explanation is that patients with lower HIV RNA levels at entry in START 
had much longer duration of untreated HIV infection when compared to those with higher HIV 
RNA levels.  A widely held hypothesis is that HIV associated damage from immune activation 
within lymphatic tissues leads to fibrosis that impairs T-cell homeostasis and immune recovery.  
Longer duration of untreated HIV infection may worsen the process of LN fibrosis and, in part, 
contribute to reduced CD4 recovery during ART treatment36,37.   
In contrast to most studies reporting age as risk factor for low CD4+ recovery11,16,33–
35,38,39
, possibly due to thymic senescence, we did not find a strong association between older age 
and low CD4+ recovery.  This may be because the great majority of participants in START were 
< 45 years of age.  
Previous studies have not investigated inflammatory and coagulation markers such as IL-
6 and D-dimer.  We did not observe an association of IL-6 with low CD4+ count recovery; 
however, we found a curvilinear association of D-dimer with low recovery.  We have previously 
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reported that both markers are associated with HIV viral load at baselines40.  With adjustment for 
HIV viral load and other factors this association persisted.     
In linear regression analysis, we demonstrated that screening and baseline CD4+ counts 
had different relationships with CD4+ change from baseline to 8 months.   The inverse 
relationship with baseline CD4+ cell count can be explained by regression to the mean. When 
this association was corrected for measurement error and temporal variability27,30, the slope 
estimate was nearly identical with the slope for screening CD4+ count. This finding may prove 
useful in other investigations that do not have the luxury of multiple readings for assessing the 
relationship of change with initial value.  
 In addition to having two pre-ART CD4+ cell counts to consider as predictors of low 
CD4+ response, other strengths of our study are the large sample size and the geographic and 
demographic diversity of the cohort.  A limitation of our study is that we do not have sufficient 
follow-up data to investigate the clinical implications of low recovery due to the small number of 
events in the immediate ART initiation group of the START trial13. Longer follow-up is 
required.   One might presume that low CD4+ recovery among those who initiate ART at counts 
> 500 cells does not carry the same risk of morbidity and mortality as those who have low 
recovery after initiating ART at lower counts. Indeed, CD4+ counts below 500 are not 
uncommon in HIV-negative individuals41.  Furthermore, we do not know the pre-HIV-infection 
CD4+ values, and hence the extent that “return” to health as a reason for lack of relatively poorer 
improvement in CD4+ cell count is not possible to determine. This issue has been less of an 
issue in prior studies assessing impact from ART in patients with lower nadir CD4+ counts, 
where it is more likely that there may have been an impact from the HIV infection on the CD4+ 
count. Based on this, it is noteworthy that screening CD4+ count did not predict low CD4+ count 
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recovery for those with lowest HIV RNA levels.  This suggests that there may be a subgroup for 
whom HIV does not impact CD4+ count and who remained at their pre-HIV set-point when 
ART was initiated. Conversely, the reduced odds of low recovery for higher screening CD4+ cell 
count in those with higher HIV RNA levels is not readily explainable this way.  It is possible 
these participants may have levels below their pre-HIV value, and their reduced odds of low 
CD4+ recovery would reflect variation in irrecoverable harm within the population from HIV.  
Overall, our results are supportive of this interpretation since a greater percentage of those with 
lower screening CD4+ cell counts (and hence more injury from HIV) had low CD4+ 
recovery.  An alternative explanation is that the results Figure 3 merely reflect variation in the 
populations selected. It is also possible that factors not yet identified are associated with low 
recovery and risk of disease. These include host genetic factors9, and these in turn could 
influence risk of clinical outcomes. Future host genetic analyses may elucidate this issue. 
 In summary, low CD4+ recovery among HIV-positive patients is frequent even among 
those who initiate ART at CD4+ levels > 500 cells/mm3.  The large number of participants with 
low recovery with early ART initiation suggests that there is much we do not know about the 
determinants of low recovery. The risk of morbidity and mortality among those who initiate 
ART at higher CD4+ counts and have low CD4+ recovery remains to be determined.  
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Figure 1. Mean CD4+ counts (cells/mm3 ± standard error of the man) during follow-up for 
participants with high recovery (CD4+ increase ≥ 50 cells/mm3 8 months after initiating ART) 
vs. low recovery (CD4+ increase < 50 cells/mm3 8 months after initiating ART). All participants 
had HIV RNA ≤ 200 copies/ml at month 8. 
 
Figure 2. Percent of participants with low CD4+ recovery after 8 months by tertiles of screening 
CD4+ (1st of 2 pre-ART CD4+ values). 
 
Figure 3. Percent of participants with low CD4+ recovery after 8 months by tertiles of screening 
CD4+ (1st of 2 pre-ART CD4+ values) and baseline HIV RNA copies/mL. Samples sizes are 
indicated for each subgroup. 
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 Table 1. Change in CD4+ Cell Count from Baseline to 8 Months Per 100 cells/mm3 
higher in Screening and Baseline CD4+ Count Levels 
 
Predictor Estimate S.E. 95% CI p-value 
Screening CD4+ (cells/mm3) 2.1 2.8 (-3.4 , 7.7) 0.45 
Baseline CD4+ (cells/mm3) -32.5 2.7 (-37.8 , -27.2) <.001 
Baseline CD4+(Blomqvist Estimator) 1.7 7.3 (-11.6 , 16.9) 0.82 
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 Table 2. Univariable and Multivariable Odds Ratios for Low CD4 Recovery. 
 
  
Univariable Multivariable 
Risk Factor OR (95% CI) p-value OR (95% CI) p-value 
Age, OR per 10 years higher 1.06 (0.97 - 1.16) 0.23 1.10 (0.98 - 1.24) 0.11 
Female 1.00 (ref.)   1.00 (ref.)   
Male 0.93 (0.75 - 1.14) 0.47 1.53 (1.12 - 2.10) 0.007 
Race         
White/Other 1.00 (ref.)   1.00 (ref.)   
Asian 1.28 (0.89 - 1.83) 0.18 1.12 (0.33 - 3.78) 0.86 
Black 1.51 (1.22 - 1.87) <.001 1.08 (0.73 - 1.59) 0.70 
Hispanic 1.17 (0.88 - 1.55) 0.27 1.28 (0.90 - 1.81) 0.17 
Geographic Location         
United States 1.00 (ref.)   1.00 (ref.)   
Africa 1.70 (1.19 - 2.44) 0.004 1.62 (1.01 - 2.58) 0.043 
Asia 1.26 (0.79 - 2.01) 0.33 1.27 (0.34 - 4.81) 0.72 
Europe & Israel 1.02 (0.72 - 1.44) 0.92 1.03 (0.68 - 1.58) 0.88 
Australia 1.09 (0.57 - 2.07) 0.80 1.09 (0.52 - 2.27) 0.82 
Latin America 1.17 (0.82 - 1.67) 0.38 1.15 (0.75 - 1.76) 0.52 
Treatment Regimen         
NNRTI + 2 NRTIs 1.00 (ref.)   1.00 (ref.)   
Protease Inhibitor + 2 NRTIs 0.67 (0.52 - 0.86) 0.002 0.78 (0.59 - 1.04) 0.09 
Integrase Inhibitor + 2 NRTIs 0.72 (0.44 - 1.17) 0.18 0.90 (0.52 - 1.56) 0.70 
Other 2.80 (0.25 - 30.99) 0.40 1.52 (0.09 - 25.75) 0.77 
Body Mass Index, OR per kg/m2 higher 0.99 (0.98 - 1.01) 0.55 0.98 (0.96 - 1.00) 0.08 
Hepatitis C Co-infection 1.06 (0.64 - 1.75) 0.84 0.99 (0.55 - 1.76) 0.96 
Hepatitis B Co-infection 1.60 (0.95 - 2.72) 0.08 1.45 (0.79 - 2.67) 0.24 
Screening CD4+, OR per 100 fewer cells/mm3 1.00 (0.95 - 1.04) 0.85 1.09 (1.03 - 1.15) 0.004 
Baseline CD8+, OR per 100 more cells/mm3 1.03 (1.02 - 1.05) <.001 1.05 (1.03 - 1.07) <.001 
Baseline HIV RNA copies/mL, OR per log10 lower 1.68 (1.50 - 1.87) <.001 1.93 (1.68 - 2.22) <.001 
Baseline IL-6 pg/mL, OR per log2 higher 1.01 (0.91 - 1.12) 0.89 1.07 (0.95 - 1.20) 0.28 
†Baseline log2 D-dimer µg/mL 1.25 (1.03 - 1.52) 0.021 1.27 (1.03 - 1.57) 0.028 
†Baseline (log2 D-dimer µg/mL)2 1.09 (1.02 - 1.17) 0.013 1.11 (1.03 - 1.19) 0.006 
Time since HIV diagnosis, OR per 1 year higher 1.04 (1.01 - 1.07) 0.011 1.03 (0.99 - 1.06) 0.15 
 
Low Recovery: Initial CD4 Recovery ≤ 50 cells/mm3 8 months after initiating ART 
High Recovery: Initial CD4 Recovery > 50 cells/mm3 8 months after initiating ART 
OR: odds ratio; 95% CI: 95% confidence interval. 
†Considering both the linear and quadratic regression coefficients in the adjusted model,the OR associated with a doubling of D-dimer from 0.323 (median) to 0.646 is 1.003. In 
the model with adjustment for other covariates and only a linear term for D-dimer, this OR was 1.01 
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